The Board of Directors of Roivant Sciences Ltd. has authorized a buyback plan on April 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 USD | -0.74% | +1.47% | +1.65% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.65% | 9.27B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Roivant Sciences Ltd. authorizes a Buyback Plan.